Precipio, Inc. PRPO

Company Overview

Precipio, Inc. (NASDAQ: PRPO) is a U.S.-based healthcare diagnostics company focused on cancer diagnostics, laboratory services, and diagnostic technologies. The company operates primarily within the oncology and pathology sectors, providing specialized diagnostic testing intended to improve the accuracy and efficiency of cancer detection and classification. Its core activities include hematopathology, molecular diagnostics, cytogenetics, and related laboratory services used by physicians, hospitals, and oncology practices.

The company’s principal revenue drivers are clinical laboratory testing services and proprietary diagnostic products designed to address diagnostic errors and workflow inefficiencies in pathology. Precipio has emphasized technologies intended to reduce misdiagnosis risk in blood cancers and other complex oncology cases. The company evolved from a broader healthcare-focused platform into a more specialized oncology diagnostics business through acquisitions, laboratory expansion, and development of proprietary testing technologies. Public disclosures and industry reporting consistently identify precision oncology diagnostics as the company’s primary strategic focus.